September 22, 2014 9:36 PM ET

Healthcare Equipment and Supplies

Company Overview of InfraReDx, Inc.

Company Overview

InfraReDx, Inc., a medical device company, develops and commercializes cardiovascular diagnostic imaging technologies for the diagnosis and treatment of coronary artery disease. It offers LipiScan IVUS coronary imaging system that combines near-infrared spectroscopy and intravascular ultrasound technologies to visualize and characterize the intracoronary lipid core plaques suspected of causing various heart attacks. The company was founded in 1998 and is based in Burlington, Massachusetts.

34 Third Avenue

Burlington, MA 01803

United States

Founded in 1998





Key Executives for InfraReDx, Inc.

Chief Executive Officer and President
Age: 68
Chief Financial Officer
Chief Operating Officer
Chief Business Officer
Age: 66
Compensation as of Fiscal Year 2014.

InfraReDx, Inc. Key Developments

Infraredx Announces the First Patient Enrolled in the Prospect II Study on the Detection and Treatment of the Vulnerable Plaques Suspected to Cause Heart Attacks

Infraredx, Inc. announced the first patient enrolled in PROSPECT II, a multi-center, prospective study designed to assess the ability of intravascular imaging to identify non-flow obstructing vulnerable plaques. Lipid core plaque (LCP), which is suspected to be vulnerable plaque, is a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System(TM), a first-in-class dual modality intravascular imaging system. The study's first patient was enrolled by David Erlinge, MD, PhD, one of the study's principal investigators, from Lund University in Sweden. The TVC Imaging System is the only device approved by the FDA to detect the presence of LCPs. The technology integrates near-infrared spectroscopy (NIRS) to detect LCPs, with enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, and is used to guide percutaneous coronary interventions (PCI). Infraredx will provide the primary funding for the study, with additional support from The Medicines Company and Abbott Vascular.

GE Capital and Healthcare Financial Services Increase Existing Credit Facility for InfraReDx, Inc. to $20 Million

GE Capital and Healthcare Financial Services announced that it has amended its existing $6.6 million senior secured credit facility to InfraReDx, Inc. to provide an additional $13.4 million multi-draw term loan facility, and to modify the terms of the existing facility. GE Capital, Healthcare Financial Services is acting as administrative agent for the credit facility. The financing will be used to support the company's commercialization efforts.

Royal Philips and Infraredx, Inc. Sign Agreement for the Resale of Infraredx, Inc.'s TVC Imaging System

Royal Philips and Infraredx, Inc. announced a non-exclusive resale agreement for Infraredx's TVC Imaging System. Under the terms of the agreement, Philips will sell Infraredx's TVC Imaging System alongside its Allura interventional X-ray systems in North America and Europe, expanding its interventional cardiology portfolio of advanced live image guidance solutions, clinical informatics and interventional tools. Coronary artery disease (CAD) is caused when plaque builds up along the inner walls of the coronary (heart) arteries, causing them to narrow and reduce blood flow to the heart muscle. It can be treated with percutaneous coronary intervention (PCI), a catheter-based procedure that is performed in a cath lab under interventional X-ray guidance. Increasingly, additional catheter-based intravascular imaging technologies, such as the TVC Imaging System, are being used to assess the structure and composition of plaques from within the blood vessel, and to guide the interventional treatment for better procedural outcomes. The TVC Imaging System is a first-in-class intravascular imaging system that integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection technology, and enhanced intravascular ultrasound (IVUS) imaging to visualize the presence of plaques, quantify the degree of vessel stenosis (narrowing) and identify plaques prone to rupturing and causing dangerous blockages.

Similar Private Companies By Industry

Company Name Region
Stealth Therapeutics, Inc. United States
R2T2 Laboratories Inc. United States
Adlens Beacon, Inc. United States
Liberate Medical, LLC United States
Interferometrics, Inc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InfraReDx, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at